Summary of main outcomes of interest by fludarabine exposure group
| Outcome . | AUC < 18 (n = 136), % (95% CI) . | AUC, 18-20 (n = 36), % (95% CI) . | AUC > 20 (n = 27), % (95% CI) . |
|---|---|---|---|
| 6-mo relapse/POD | 57 (48-65) | 32 (17-47) | 43 (23-62) |
| 1-y PFS | 39 (31-48) | 66 (52-84) | 46 (30-70) |
| 1-y OS | 58 (50-67) | 77 (64-92) | 66 (50-87) |
| 1-y NRM | 5 (2-9) | 3 (0.2-13) | 11 (3-26) |
| Day +30 all-grade CRS | 79 (71-85) | 78 (60-89) | 85 (63-95) |
| Day +30 all-grade ICANS | 44 (36-53) | 56 (38-70) | 70 (49-84) |
| Day +30 grade ≥3 ICANS | 30 (22-38) | 38 (23-55) | 37 (19-55) |
| Outcome . | AUC < 18 (n = 136), % (95% CI) . | AUC, 18-20 (n = 36), % (95% CI) . | AUC > 20 (n = 27), % (95% CI) . |
|---|---|---|---|
| 6-mo relapse/POD | 57 (48-65) | 32 (17-47) | 43 (23-62) |
| 1-y PFS | 39 (31-48) | 66 (52-84) | 46 (30-70) |
| 1-y OS | 58 (50-67) | 77 (64-92) | 66 (50-87) |
| 1-y NRM | 5 (2-9) | 3 (0.2-13) | 11 (3-26) |
| Day +30 all-grade CRS | 79 (71-85) | 78 (60-89) | 85 (63-95) |
| Day +30 all-grade ICANS | 44 (36-53) | 56 (38-70) | 70 (49-84) |
| Day +30 grade ≥3 ICANS | 30 (22-38) | 38 (23-55) | 37 (19-55) |
AUC in mgh/L.
NRM, nonrelapse mortality.